A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase

被引：0
|
作者：
Bardos, Jennifer N. [1 ]
Goadsby, Peter J. [2 ,3 ]
Dodick, David [4 ]
Leone, Massimo [5 ]
Oakes, Tina M. [1 ]
Martinez, James M. [1 ]
Millen, Brian A. [1 ]
Zhou, Chunmei [1 ]
Dowsett, Sherie A. [1 ]
Aurora, Sheena K. [1 ]
Yang, Jyun Yan [1 ]
Conley, Robert [1 ,6 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[4] Mayo Clin, Phoenix, AZ USA
[5] IRCCS Fdn Carlo Besta Neurol Inst, Milan, Italy
[6] Univ Maryland, Sch Med, Indianapolis, IN USA
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Plen02.004
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of eprosartan in patients with essential hypertension: Results of an 8-week, double-blind, placebo-controlled, multicenter trial
    Weber, M
    JOURNAL OF HYPERTENSION, 1998, 16 : S245 - S245
  • [22] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    CEPHALALGIA, 2017, 37 : 338 - 338
  • [23] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, H. C.
    Wang, S.
    Skljarevski, V
    Ahl, J.
    Millen, B.
    Aurora, S. K.
    Yang, J.
    HEADACHE, 2017, 57 (08): : 1336 - 1337
  • [24] A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [25] A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder
    Khan, Arif
    Cutler, Andrew J.
    Kajdasz, Daniel K.
    Gallipoli, Susan
    Athanasiou, Maria
    Robinson, Donald S.
    Whalen, Heidi
    Reed, Carol R.
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (04) : 441 - +
  • [26] An 8-week, randomized, double-blind, placebo-controlled, multicenter study of esreboxetine administered once daily in patients with fibromyalgia
    Arnold, Lesley
    Chatamra, Krai
    Hirsch, Ian
    Stoker, Malcolm
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S434 - S434
  • [27] 100% RESPONSE RATE TO GALCANEZUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
    Nagy, A. J.
    Pearlman, E.
    Ruff, D.
    Day, K.
    Aurora, S. K.
    Rosen, N.
    CEPHALALGIA, 2018, 38 : 63 - 64
  • [28] 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies
    Nagy, Abraham Jim
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Rosen, Noah
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [29] A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study
    Mulleners, W.
    Kim, B.
    Lainez, M. J.
    Lanteri-Minet, M.
    Aurora, S. K.
    Nichols, R. M.
    Wang, S.
    Tockhorn-Heidenreich, A.
    Detke, H.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [30] Intranasal sumatriptan in cluster headache - Randomized placebo-controlled double-blind study
    van Vliet, JA
    Bahra, A
    Martin, V
    Ramadan, N
    Aurora, SK
    Mathew, NT
    Ferrari, MD
    Goadsby, PJ
    NEUROLOGY, 2003, 60 (04) : 630 - 633
12345